These findings should encourage the development of targeted therapies that specifically inhibit TWIST1 and/or miR-10b expression levels in cancer cells in order to reduce the risk of bone metastasis formation in breast cancer patients. This evidence concerns the gene TWIST1 and breast carcinoma.